Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen
- PMID: 20006859
- DOI: 10.1016/j.juro.2009.10.022
Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen
Abstract
Purpose: Undetected cancer in repeat transrectal ultrasound guided prostate biopsies in patients with increased prostate specific antigen greater than 4 ng/ml is a considerable concern. We investigated the tumor detection rate of tumor suspicious regions on multimodal 3 Tesla magnetic resonance imaging and subsequent magnetic resonance imaging guided biopsy in 68 men with repeat negative transrectal ultrasound guided prostate biopsies. We compared results to those in a matched transrectal ultrasound guided prostate biopsy population. Also, we determined the clinical significance of detected tumors.
Materials and methods: A total of 71 consecutive patients with prostate specific antigen greater than 4 ng/ml and 2 or greater negative transrectal ultrasound guided prostate biopsy sessions underwent multimodal 3 Tesla magnetic resonance imaging. In 68 patients this was followed by magnetic resonance imaging guided biopsy directed toward tumor suspicious regions. A matched multisession transrectal ultrasound guided prostate biopsy population from our institutional database was used for comparison. The clinical significance of detected tumors was established using accepted criteria, including prostate specific antigen, Gleason grade, stage and tumor volume.
Results: The tumor detection rate of multimodal 3 Tesla magnetic resonance imaging guided biopsy was 59% (40 of 68 cases) using a median of 4 cores. The tumor detection rate was significantly higher than that of transrectal ultrasound guided prostate biopsy in all patient subgroups (p <0.01) except in those with prostate specific antigen greater than 20 ng/ml, prostate volume greater than 65 cc and prostate specific antigen density greater than 0.5 ng/ml/cc, in which similar rates were achieved. Of the 40 patients with identified tumors 37 (93%) were considered highly likely to harbor clinically significant disease.
Conclusions: Multimodal magnetic resonance imaging is an effective technique to localize prostate cancer. Magnetic resonance imaging guided biopsy of tumor suspicious regions is an accurate method to detect clinically significant prostate cancer in men with repeat negative biopsies and increased prostate specific antigen.
Copyright 2010 American Urological Association. Published by Elsevier Inc. All rights reserved.
Comment in
-
Editorial comment.J Urol. 2010 Feb;183(2):527-8; discussion 528. doi: 10.1016/j.juro.2009.10.095. Epub 2009 Dec 14. J Urol. 2010. PMID: 20006885 No abstract available.
-
Re: Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.Eur Urol. 2011 Jul;60(1):178. doi: 10.1016/j.eururo.2011.04.015. Eur Urol. 2011. PMID: 21640693 No abstract available.
Similar articles
-
Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naïve men with elevated prostate specific antigen.J Urol. 2014 Nov;192(5):1374-9. doi: 10.1016/j.juro.2014.05.090. Epub 2014 May 24. J Urol. 2014. PMID: 24866597 Clinical Trial.
-
Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer.J Urol. 2013 Oct;190(4):1380-6. doi: 10.1016/j.juro.2013.04.043. Epub 2013 Apr 19. J Urol. 2013. PMID: 23608676 Clinical Trial.
-
Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml.NMR Biomed. 2007 Feb;20(1):11-20. doi: 10.1002/nbm.1083. NMR Biomed. 2007. PMID: 16894640
-
[Transrectal ultrasound-guided punch biopsies of the prostate. Indication, technique, results, and complications].Urologe A. 2003 Sep;42(9):1188-95. doi: 10.1007/s00120-003-0422-4. Urologe A. 2003. PMID: 14504751 Review. German.
-
Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study.J Urol. 2001 Sep;166(3):856-60. J Urol. 2001. PMID: 11490233 Review.
Cited by
-
Reliability of Multiparametric Magnetic Resonance Imaging in Patients with a Previous Negative Biopsy: Comparison with Biopsy-Naïve Patients in the Detection of Clinically Significant Prostate Cancer.Diagnostics (Basel). 2023 Jun 1;13(11):1939. doi: 10.3390/diagnostics13111939. Diagnostics (Basel). 2023. PMID: 37296791 Free PMC article.
-
Role of MRI-US Fusion Biopsy in Diagnosing Prostatic Cancer.Indian J Surg Oncol. 2017 Sep;8(3):357-360. doi: 10.1007/s13193-016-0612-3. Epub 2017 Mar 2. Indian J Surg Oncol. 2017. PMID: 36118387 Free PMC article.
-
Paradigm Shift in Prostate Cancer Diagnosis: Pre-Biopsy Prostate Magnetic Resonance Imaging and Targeted Biopsy.Korean J Radiol. 2022 Jun;23(6):625-637. doi: 10.3348/kjr.2022.0059. Epub 2022 May 9. Korean J Radiol. 2022. PMID: 35555886 Free PMC article. Review.
-
Evaluating the diagnostic role of in-bore magnetic resonance imaging guided prostate biopsy: a single-centre study.ANZ J Surg. 2022 Jun;92(6):1486-1491. doi: 10.1111/ans.17713. Epub 2022 Apr 28. ANZ J Surg. 2022. PMID: 35482421 Free PMC article.
-
The Need to Pair Molecular Monitoring Devices with Molecular Imaging to Personalize Health.Mol Imaging Biol. 2022 Oct;24(5):675-691. doi: 10.1007/s11307-022-01714-4. Epub 2022 Mar 7. Mol Imaging Biol. 2022. PMID: 35257276 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical